Advances in bumped kinase inhibitors for human and animal therapy for cryptosporidiosis.

Hulverson, Matthew A; Choi, Ryan; Arnold, Samuel L M; Schaefer, Deborah A; Hemphill, Andrew; McCloskey, Molly C; Betzer, Dana P; Müller, Joachim; Vidadala, Rama S R; Whitman, Grant R; Rivas, Kasey L; Barrett, Lynn K; Hackman, Robert C; Love, Melissa S; McNamara, Case W; Shaughnessy, Thomas K; Kondratiuk, Alison; Kurnick, Matthew; Banfor, Patricia N; Lynch, James J; ... (2017). Advances in bumped kinase inhibitors for human and animal therapy for cryptosporidiosis. International journal for parasitology, 47(12), pp. 753-763. Elsevier 10.1016/j.ijpara.2017.08.006

Text 1-s2.0-S0020751917302515-main.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (1MB)

Improvements have been made to the safety and efficacy of bumped kinase inhibitors, and they are advancing toward human and animal use for treatment of cryptosporidiosis. As the understanding of bumped kinase inhibitor pharmacodynamics for cryptosporidiosis therapy has increased, it has become clear that better compounds for efficacy do not necessarily require substantial systemic exposure. We now have a bumped kinase inhibitor with reduced systemic exposure, acceptable safety parameters, and efficacy in both the mouse and newborn calf models of cryptosporidiosis. Potential cardiotoxicity is the limiting safety parameter to monitor for this bumped kinase inhibitor. This compound is a promising pre-clinical lead for cryptosporidiosis therapy in animals and humans.

Interest & Impact

Downloads

0 since deposited on 17 May 2018
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item